摘要
目的研究益生菌颗粒在初治肺结核患者T淋巴细胞亚群中的影响。方法纳入2021年11月-2022年11月在本院确诊并接受系统治疗的120例初治肺结核患者,按照随机数字表法平均分为试验组(60例)和对照组(60例)。对照组给予标准2HRZE/4HR抗结核方案治疗,试验组在对照组基础上应用益生菌颗粒治疗。比较两组患者治疗2个月前后CD4+、CD8+及Th17/Treg比值水平。结果经过2个月治疗,试验组CD4+、CD4+/CD8+比值、Treg细胞比例、Treg/Th17比值水平高于对照组,Th17水平低于对照组,差异具有统计学意义(P<0.05)。结论益生菌辅助治疗能够改善机体免疫状态,为肺结核患者综合性治疗提供新的依据。
Objective To study the effect of probiotic granules on T lymphocyte subsets in newly treated pulmonary tuberculosis patients.Methods A total of 120 patients with initially treated pulmonary tuberculosis who were diagnosed and received systematic treatment in our hospital from November 2021 to November 2022 were included and divided into experimental group(60 cases)and control group(60 cases)according to random number table method.The control group was treated with standard 2HRZE/4HR anti-tuberculosis regimen,while the experimental group was treated with probiotic granules on the basis of the control group.The levels of CD4+,CD8+and Th17/Treg ratio before and after 2 months of treatment were compared between the two groups.Results After 2 months of treatment,the levels of CD4+,CD4+/CD8+ratio,Treg cell proportion and Treg/Th17 ratio in experimental group were higher than those in control group,while Th17 level was lower than that in control group,the difference was statistically significant(P<0.05).Conclusion Probiotics adjuvant therapy can improve the immune status of the body and provide a new basis for the comprehensive treatment of tuberculosis patients.
作者
刘欣
李健
哈力木拉提·艾木肉拉
阿尔泰
LIU Xin;LI Jian;Halimulati Aimuroula;Aertai(Department of clinical nutrition,The Eighth Affiliated Hospital of Xinjiang Medical University,Urumqi,830049,China;Generalsurgery,The Eighth Affiliated Hospital of Xinjiang Medical University,Urumqi,830049,China;Respiratory center,The Eighth Affiliated Hospital of Xinjiang Medical University,Urumqi,830049,China;Science and education department,The Eighth Affiliated Hospital of Xinjiang Medical University,Urumqi,830049,China)
出处
《新疆医学》
2023年第5期521-523,共3页
Xinjiang Medical Journal
基金
省部共建中亚高发病成因与防治国家重点实验室开放课题项目(项目编号:SKL-HIDCA-2021-BF5)